Trisodium 5-[[4-chloro-6-(ethylphenylamino)-1,3,5-triazin-2-yl]amino]-4-hydroxy-3-[(2-sulphonatophenyl)azo]naphthalene-2,7-disulphonate

Acute Toxicity: dermal

Some information in this page has been claimed confidential.

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

2010-01-05 till 2010-01-26

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Guideline-conform study under GLP without deviations

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Reference

Endpoint:

acute toxicity: dermal

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Reason / purpose for cross-reference:

read-across source

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: no statistical analysis was performed

Interpretation of results:

GHS criteria not met

Conclusions:

Based on the read-across data generated from the acute dermal toxicity study with FAT 40850/A, the acute dermal median lethal dose (LD50) of FAT 40034 in Wistar rats is greater than 2000 mg/kg body weight.

Executive summary:

Data on acute dermal toxicity study was not available for the target substance (FAT 40034). To fill the data gaps, read across approach is adapted using similar substance Reactive Red 286 (FAT 40850/A). Read-across is claimed basis of structural relationship of the target and the source chemicals. Read-across substance have been investigated for acute dermal toxicity. Five male and five female Wistar rats were treated with FAT 40850/A at 2000 mg/kg by dermal application in accordance with OECD guideline 402 and EU Method B.3 and GLP. The test item was formulated in purified water at a concentration of 0.33 g/mL and administered at a volume dosage of 6 mL/kg. The application period was 24 h. The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs within the first 30 minutes and at approximately 1, 2, 3 and 5 h after treatment on test day 1 and once daily during test days 2-15. Local signs were evaluated once daily after removal of the dressing on test day 2 up to test day 15. Mortality/viability was recorded within the first 30 minutes and at approximately 1, 2, 3 and 5 h after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically. No intercurrent deaths occurred during the course of the study. No clinical signs were recorded throughout the complete observation period. In all animals, strong violet staining produced by the test item was noted on the treated skin area from test day 2 up to test day 6 or 9. However, this staining prevented the assessment of possible erythema. When assessable, no local dermal signs were observed in all animals. The body weight of all animals was considered to be within the range commonly recorded for this strain and age. No macroscopic findings were observed at necropsy. No deaths were found during study period. Under the study conditions, based on this read across data generated with Reactive Red 286 (FAT 40850/A), the acute dermal median lethal dose (LD₅₀) of Reactive Red 024:1 is also considered to be greater than 2000 mg/kg.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2010

Report date:

2010

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Remarks:

Swiss GLP

Test type:

standard acute method

Limit test:

yes

Test material

Test material information

Constituent 1

Details on test material:

- Name of test material (as cited in study report): FAT 40850/A TE
- Substance type: textile dyestuff
- Physical state: red powder
- Analytical purity: ca. 63 % of all colored components
- Lot/batch No.: BOP 07-09
- Expiration date of the lot/batch: 2014-07-31
- Storage condition of test material: At room temperature at about 20 °C

Specific details on test material used for the study:

SOURCE OF TEST MATERIAL
- Source and lot/batch number of test material: TZ 5978 / BOP 07-09
- Expiration date of the lot/batch: 31-Jul-2014

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At room temperature (range of 20 ± 5 °C), light protected.
- Stability under storage conditions: Stable under storage conditions

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS RccHan: WIST(SPF)
- Source: Harlan Laboratories B.V. Kreuzelweg 53 5961 NM Horst / The Netherlands Postbus 6174 5960 AD Horst / The Netherlands
- Age at study initiation: Males: 9 weeks, Females: 11 weeks
- Weight at study initiation: Males 244.8 - 261.9 g ; Females: 191.8 - 210.3g
- Fasting period before study: no data
- Housing: During acclimatization in groups of five per sex in Makrolon type-4 cages with standard softwood bedding. Individually in Makrolon type-3 cages with standard softwood bedding
- Diet: Pelleted standard Provimi Kliba 3433 rat/mouse maintenance diet, batch no. 30/09 (Provimi Kliba AG, 4303 Kaiseraugst / Switzerland) ad libitum.
- Water: Community tap water from Füllinsdorf ad libitum.
Acclimatization: Under laboratory conditions, after health examination. Only animals without any visible signs of illness were used for the study.of illness were used for the study.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): relative humidity between 30-70 (values above 70% during cleaning process possible)
- Air changes (per hr): Air-conditioned with 10-15 air changes per hour
- Photoperiod (hrs dark / hrs light): automatically controlled light cycle of 12 h light and 12 h dark, music during the daytime light period.

Administration / exposure

Type of coverage:

semiocclusive

Details on dermal exposure:

TEST SITE
- Area of exposure: no data
- % coverage: approx. 10 % of the body surface
- Type of wrap if used: skin with a syringe and covered with a surgical gauze pad (ca. 5 x 5 cm) held in contact with the skin by means of an adhesive hypoallergenic aerated semi-occlusive dressing and an elastic adhesive restrainer bandage wrapped around the abdomen.


REMOVAL OF TEST SUBSTANCE
- Washing (if done): yes, flushed with lukewarm water and drapped off with disposable paper towels.
- Time after start of exposure: 24 h

TEST MATERIAL AND VEHICLE
- Amount(s) applied (volume or weight with unit): 6 mL/kg
- Concentration (if solution): dose: 2000 mg/kg BW
- Constant volume or concentration used: yes
- test item was weighed into a tared glass beaker on a suitable precision balance and the vehicle was added (weight:volume).

Duration of exposure:

24h

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

not required

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:

Viability / Mortality: Daily during the acclimatization period, within the first 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15.

Clinical Signs: Daily during the acclimatization period, within the first 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1. Once daily during days 2-15.

Local Dermal Signs: Once daily during days 2 (following dressing removal) through day 15 using the numerical scoring system described in Appendix I.

Body Weights: On test days 1 (prior to administration), 8 and 15.

- Necropsy of survivors performed: yes
- Other examinations performed: macroscopic examinations were performed. An external examination and opening of the abdominal and thoracic cavities for examinations of major organs were performed. The appearance of any macroscopic abnormalities was recorded.No organs or tissues were retained.

Statistics:

No statistical analysis was used.

Results and discussion

Effect levels

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: no statistical analysis was performed

Mortality:

No intercurrent deaths occurred during the course of the study.

Clinical signs:

other: No clinical signs were recorded throughout the complete observation period.

Gross pathology:

No macroscopic findings were recorded at necropsy.

Other findings:

In all animals, strong violet staining produced by the test item was noted on the treated skin area from test day 2 up to test day 6 (males) or 9 (females). However, this staining prevented the assessment of a possible erythema. When assessable, no local dermal signs were observed in all animals.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

The median lethal dose (LD50) of FAT 40850/A after single dermal administration to Wistar rats of both sexes is greater than 2000 mg/kg body weight.

Executive summary:

Five male and five female Wistar rats were treated with FAT 40850/A TE at 2000 mg/kg by dermal application in accordance with OECD guideline 402 and EU Method B.3 and GLP. The test item was formulated in purified water at a concentration of 0.33 g/mL and administered at a volume dosage of 6 mL/kg. The application period was 24 hours. The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs within the first 30 minutes and at approximately 1, 2, 3 and 5 hours after treatment on test day 1 and once daily during test days 2-15. Local signs were evaluated once daily after removal of the dressing on test day 2 up to test day 15. Mortality/viability was recorded within the first 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically. No intercurrent deaths occurred during the course of the study. No clinical signs were recorded throughout the complete observation period. In all animals, strong violet staining produced by the test item was noted on the treated skin area from test day 2 up to test day 6 or 9. However, this staining prevented the assessment of possible erythema. When assessable, no local dermal signs were observed in all animals. The body weight of all animals was considered to be within the range commonly recorded for this strain and age. No macroscopic findings were observed at necropsy. The median lethal dose (LD₅₀) of FAT 40850/A after single dermal administration to Wistar rats of both sexes is greater than 2000 mg/kg body weight.